Targeting Endoglin Expressing Cells in the Tumor Microenvironment Does Not Inhibit Tumor Growth in a Pancreatic Cancer Mouse Model
Mark J A Schoonderwoerd,Sarah K Hakuno,Martijn Sassen,Eleonore B Kuhlemaijer,Madelon Paauwe,Marije Slingerland,Marieke F Fransen,Lukas J A C Hawinkels,Mark JA Schoonderwoerd,Lukas JAC Hawinkels
DOI: https://doi.org/10.2147/OTT.S322276
IF: 4
2021-10-30
OncoTargets and Therapy
Abstract:Mark JA Schoonderwoerd, 1, &ast Sarah K Hakuno, 1, &ast Martijn Sassen, 1 Eleonore B Kuhlemaijer, 1 Madelon Paauwe, 1 Marije Slingerland, 2 Marieke F Fransen, 3 Lukas JAC Hawinkels 1 1 Department of Gastroenterology-Hepatology, Leiden University Medical Center, Leiden, the Netherlands; 2 Department of Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands; 3 Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, the Netherlands &astThese authors contributed equally to this work Correspondence: Lukas JAC Hawinkels Tel +31 71 526 6736 Email Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer and is known to have low immunogenicity and an immunosuppressive microenvironment. It is also characterized by high accumulation of dense stroma, composed of mostly cancer-associated fibroblasts (CAFs). Multiple subsets of CAFs are described, with one of them expressing the transforming growth factor (TGF)-β co-receptor endoglin. In previous work, we and others have shown that endoglin-expressing CAFs stimulate tumor progression and metastasis. Therefore, in this study, we set out to investigate the role of endoglin-expressing CAFs in pancreatic cancer progression. Methods: First, we investigated the expression of endoglin on CAFs in both human tissues as well as a mouse model for PDAC. Since CAF-specific endoglin expression was high, we targeted endoglin by using the endoglin neutralizing antibody TRC105 in the murine KPC model for PDAC. Results: Although some signs of immune activation were observed, TRC105 did not affect tumor growth. Since 90% of the CD8+ T-cells expressed the immune checkpoint PD-1, we investigated the combination with a PD1 checkpoint inhibitor, which did not enhance therapeutic responses. Finally, genetic deletion of endoglin from collagen 1a1 expressing cells also did not affect the growth of the mouse KPC tumors. Conclusion: Our results show that although endoglin is highly expressed on PDAC-CAFs and signaling is efficiently inhibited by TRC105, this does not result in decreased tumor growth in the KPC model for pancreatic cancer. Keywords: endoglin, PDAC, cancer-associated fibroblasts, TRC105, stroma, KPC Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal forms of cancer with a 5-year survival rate of only 7%. The most common mutations are activating mutations in KRAS (95%), loss of P53 (75%) and/or Smad4 (55%). This type of cancer is known to have low immunogenicity and to display an immunosuppressive microenvironment. This has resulted in the fact that immunotherapy through checkpoint inhibition has shown limited clinical success. The immune system has a crucial role in cancer progression and PDAC is capable of using various mechanisms for immune evasion, such as recruitment of regulatory immune cells, the secretion of immunosuppressive chemokines and the expression of cell-surface proteins, such as programmed death-ligand 1 (PD-L1), cytotoxic T-lymphocyte associated protein 4 (CTLA4) and colony-stimulating factor (CSF)-1. 1 Next to the immune component of the tumor microenvironment (TME), PDAC is typically characterized by high accumulation of non-tumor cells together called the tumor stroma, which has been correlated to the poor survival of PDAC patients, 2 but also of various other solid tumors like breast-, 3 and colorectal cancer. 4 Cancer-associated fibroblasts (CAFs) are the most abundant cell type in the tumor stroma and exhibit diverse functions, including extracellular matrix deposition and remodeling. 5 CAFs can influence tumor progression and metastasis, for example via interactions with cancer cells and infiltrating immune cells. 6 Therefore, CAFs have been proposed as a potential target for therapeutic interventions in PDAC. 7 More recent work has, however, revealed that multiple subsets of CAFs exist in PDAC, 8,9 which can stimulate or inhibit tumor progression. This was further emphasized by showing that the depletion of all α-SMA expressing cells in a murine model for PDAC can increase tumor aggressiveness. 10 Our recent work in colorectal cancer revealed a subset of α-SMA positive CAFs that express the Transforming Growth Factor (TGF)-β co-receptor endoglin. The abundance of endoglin-expressing CAFs was related to invasive behavior and increased risk of metastasis in colorectal cancer and in a murine model for prostate cancer. 11,12 Endoglin is a transmembrane co-receptor for TGF-β ligands (mainly bone morphogenetic protei -Abstract Truncated-
oncology,biotechnology & applied microbiology